Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 360 results for eq-5d

  1. For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    recommended that data are collected using validated measure(s) of HRQoL, including EQ-5D. Source guidance details Comes from guidance...

    Research recommendation
    Published
    26 October 2020

  2. Effect of specialist services on health-related quality of life:- For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    recommended that data are collected using validated measure(s) of HRQoL,including EQ-5D. Source guidance details Comes from guidance...

    Research recommendation
    Published
    9 June 2015

  3. Vismodegib for treating basal cell carcinoma (TA489)

    Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    22 November 2017
    View recommendations

    Sections for TA489

  4. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

    Technology appraisal guidance
    Published
    17 November 2021
    View recommendations

    Sections for TA747

  5. Pharmacological management of peripheral spondyloarthritis:- What is the comparative effectiveness and cost effectiveness of standard DMARDs for managing peripheral spondyloarthritis, and is this effectiveness affected by differences in dose escalation protocols?

    outcome measures) both health-related quality of life (measured using the EQ-5D) and health service resource use, to enable the results...

    Research recommendation
    Published
    4 May 2017

  6. Biological therapies for peripheral spondyloarthritis:- What is the effectiveness and cost effectiveness of biological DMARDs in people with persistent peripheral spondyloarthritis (excluding psoriatic arthritis) or undifferentiated spondyloarthritis?

    outcome measures) both health-related quality of life (measured using the EQ-5D) and health service resource use, to enable the results...

    Research recommendation
    Published
    4 May 2017

  7. Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma (TA1149)

    Evidence-based recommendations on belantamab mafodotin (Blenrep) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    30 April 2026
    View recommendations

    Sections for TA1149

  8. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA312

  9. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

    Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.

    Technology appraisal guidance
    Published
    23 January 2013
    View recommendations

    Sections for TA272

  10. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.

    Technology appraisal guidance
    Published
    25 October 2023
    View recommendations

    Sections for TA926

  11. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over (TA1093)

    Evidence-based recommendations on idebenone (Raxone) for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over.

    Technology appraisal guidance
    Published
    28 August 2025

    Sections for TA1093

  12. Extracorporeal shockwave therapy for Achilles tendinopathy (HTG426)

    Evidence-based recommendations on extracorporeal shockwave therapy for treating Achilles tendinopathy in adults. This involves passing shockwaves through the skin to the affected area.

    HealthTech guidance
    Published
    21 December 2016
    View recommendations

    Sections for HTG426

  13. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.

    Technology appraisal guidance
    Last updated
    20 May 2024
    View recommendations

    Sections for TA298

  14. Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

    Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults

    Technology appraisal guidance
    Published
    28 November 2012
    View recommendations

    Sections for TA266

  15. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Last updated
    1 May 2024
    View recommendations

    Sections for TA540